|
US5217879A
(en)
|
1989-01-12 |
1993-06-08 |
Washington University |
Infectious Sindbis virus vectors
|
|
WO1996031776A1
(en)
|
1995-04-06 |
1996-10-10 |
Miltenyi Bioteh, Inc. |
Multiparameter cell separation using releasable colloidal magnetic particles
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
US6458560B1
(en)
|
1996-04-05 |
2002-10-01 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
JP2002509729A
(ja)
*
|
1998-03-27 |
2002-04-02 |
サイトス バイオテクノロジー アーゲー |
誘導性のアルファウイルス遺伝子発現系
|
|
AU4932199A
(en)
|
1998-07-31 |
2000-02-21 |
Haruo Sugiyama |
Cancer antigens based on tumor suppressor gene wt1 product
|
|
US8647864B2
(en)
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
|
DE60044125D1
(de)
|
1999-04-14 |
2010-05-20 |
Novartis Vaccines & Diagnostic |
Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
|
|
ES2288473T3
(es)
|
1999-05-18 |
2008-01-16 |
Dnavec Research Inc. |
Vector de virus deficiente en el gen de la envoltura de paramyxoviridae.
|
|
JP4608210B2
(ja)
|
2001-05-31 |
2011-01-12 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
キメラアルファウイルスレプリコン粒子
|
|
US20030232324A1
(en)
|
2001-05-31 |
2003-12-18 |
Chiron Corporation |
Chimeric alphavirus replicon particles
|
|
ES2330202T5
(es)
|
2001-09-06 |
2014-01-20 |
Alphavax, Inc. |
Sistemas vectores basados en replicones de alfavirus
|
|
MXPA05001644A
(es)
|
2002-08-13 |
2005-04-19 |
Akzo Nobel Nv |
Replicones de pestivirus que no expresan proteina c y/o e1, y particulas virales infecciosas que los contienen y pueden usarse en vacunas.
|
|
CA2499404A1
(en)
*
|
2002-09-18 |
2004-04-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services |
Recovery of recombinant human parainfluenza virus type 2 (hpiv2) from cdna and use of recombinant hpiv2 in immunogenic compositions and as vectors to elicit immune responses against piv and other human pathogens
|
|
WO2004055161A2
(en)
|
2002-12-12 |
2004-07-01 |
The Board Of Regents Of The University Of Texas System |
Large scale production of packaged alphavirus replicons
|
|
US7078218B2
(en)
|
2002-12-13 |
2006-07-18 |
Alphavax, Inc. |
Alphavirus particles and methods for preparation
|
|
US7442381B2
(en)
|
2003-03-20 |
2008-10-28 |
Alphavax, Inc. |
Alphavirus replicons and helper constructs
|
|
US20050282279A1
(en)
*
|
2003-05-29 |
2005-12-22 |
Hwu Paul L |
Expression vector encoding coronavirus-like particle
|
|
WO2004108937A1
(en)
*
|
2003-06-04 |
2004-12-16 |
Bioleaders Corporation |
Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
|
|
KR20060017635A
(ko)
|
2003-06-05 |
2006-02-24 |
와이어쓰 홀딩스 코포레이션 |
베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
|
|
CN1989250B
(zh)
|
2004-05-18 |
2013-11-20 |
阿尔法瓦克斯公司 |
Tc-83衍生的甲病毒属载体、颗粒和方法
|
|
US7332322B2
(en)
|
2004-09-14 |
2008-02-19 |
Ilya Frolov |
Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
|
|
US7998733B2
(en)
*
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
|
JP4478788B2
(ja)
|
2005-05-27 |
2010-06-09 |
独立行政法人産業技術総合研究所 |
センダイウイルス温度感受性株由来のウイルスベクター
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP1951281B1
(en)
|
2005-10-17 |
2015-04-15 |
Sloan Kettering Institute For Cancer Research |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
KR101499750B1
(ko)
|
2006-02-27 |
2015-03-06 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
가감염성 플라비바이러스 및 이들의 용도
|
|
DK2099485T3
(en)
|
2006-11-03 |
2018-05-22 |
Alphavax Inc |
Alphavirus and alphavirus replica particle formulations and associated methods
|
|
BRPI0808084A2
(pt)
|
2007-02-27 |
2014-07-22 |
Int Inst Cancer Immunology Inc |
Método para ativação de células t auxiliadoras e composição para uso no método.
|
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
|
WO2008136438A1
(ja)
*
|
2007-04-27 |
2008-11-13 |
Kyushu University, National University Corporation |
遺伝子治療用ウイルスベクター
|
|
AU2008338803B2
(en)
*
|
2007-11-26 |
2015-02-05 |
Glaxosmithkline Biologicals S.A. |
Methods of generating alphavirus particles
|
|
CA2940962C
(en)
|
2007-12-05 |
2018-07-24 |
International Institute Of Cancer Immunology, Inc. |
Cancer vaccine composition
|
|
KR101668849B1
(ko)
|
2008-01-24 |
2016-10-24 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
|
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
|
WO2010008054A1
(ja)
|
2008-07-16 |
2010-01-21 |
ディナベック株式会社 |
染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
|
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
WO2012051211A2
(en)
|
2010-10-11 |
2012-04-19 |
Novartis Ag |
Antigen delivery platforms
|
|
WO2012106403A2
(en)
|
2011-02-01 |
2012-08-09 |
Uab Research Foundation |
Methods and compositions for pseudoinfectious alphaviruses
|
|
MX350258B
(es)
*
|
2011-07-06 |
2017-08-31 |
Novartis Ag |
Emulsiones cationicas de aceite en agua.
|
|
AU2013207669C1
(en)
|
2012-01-13 |
2018-05-31 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
PL2852671T3
(pl)
|
2012-05-21 |
2019-06-28 |
The Regents Of The University Of California |
Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
|
|
US8961995B2
(en)
|
2012-09-20 |
2015-02-24 |
Uab Research Foundation |
Methods and compositions for alphavirus replicons
|
|
US9447422B2
(en)
|
2012-12-06 |
2016-09-20 |
Synthetic Genomics, Inc. |
Autonomous replication sequences and episomal DNA molecules
|
|
RS61173B1
(sr)
|
2013-01-15 |
2021-01-29 |
Memorial Sloan Kettering Cancer Center |
Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
KR102503695B1
(ko)
|
2013-02-28 |
2023-02-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
줄기세포를 동원하기 위한 방법 및 조성물
|
|
EP3782628B1
(en)
|
2013-03-15 |
2024-08-07 |
Elixirgen Therapeutics, Inc. |
Methods of using zscan4 for rejuvenating human cells
|
|
WO2014200910A2
(en)
|
2013-06-10 |
2014-12-18 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
US10975358B2
(en)
*
|
2013-09-24 |
2021-04-13 |
Id Pharma Co., Ltd. |
Method for improving efficiency of inducing pluripotent stem cell
|
|
EA039060B1
(ru)
*
|
2013-12-20 |
2021-11-29 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Вариант вируса ppcc, способ его получения с помощью молекулы нуклеиновой кислоты, конструкции днк или клетки и его применение для лечения и профилактики ррсс
|
|
US10266834B2
(en)
|
2014-02-13 |
2019-04-23 |
Synthetic Genomics, Inc. |
Recombinant RNA particles and methods of producing proteins
|
|
US10174317B2
(en)
|
2014-02-13 |
2019-01-08 |
Synthetic Genomics, Inc. |
Recombinant RNA particles and methods of use
|
|
US20180195085A1
(en)
|
2015-02-02 |
2018-07-12 |
Id Pharma Co., Ltd. |
Improved negative-strand rna viral vector
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
IL294183B2
(en)
*
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
US10695385B2
(en)
|
2015-06-25 |
2020-06-30 |
National University Corporation Kobe University |
Oral cancer vaccine
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP3334755B1
(en)
|
2015-08-10 |
2020-04-08 |
Cellivery Therapeutics, Inc. |
Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
|
|
US10166281B2
(en)
|
2015-09-04 |
2019-01-01 |
Vlp Therapeutics, Llc |
Method and composition for modulating immune response
|
|
US12252700B2
(en)
|
2015-11-13 |
2025-03-18 |
Id Pharma Co., Ltd. |
Paramyxovirus vector
|
|
US10801041B2
(en)
|
2015-11-18 |
2020-10-13 |
Orbis Health Solutions, Llc |
T7 alpha viral vector system
|
|
SMT202200370T1
(it)
|
2015-11-20 |
2022-11-18 |
Memorial Sloan Kettering Cancer Center |
Composizione per il trattamento del cancro
|
|
GB201603374D0
(en)
|
2016-02-26 |
2016-04-13 |
Ucl Business Plc |
Packaging cell
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
BE1024796B9
(fr)
|
2016-06-02 |
2019-01-08 |
Glaxosmithkline Biologicals Sa |
Constructions antigeniques du virus zika
|
|
US20190216956A1
(en)
*
|
2016-07-27 |
2019-07-18 |
The Trustees Of Columbia University In The City Of New York |
Compositions for radiotherapy and uses thereof
|
|
KR102718353B1
(ko)
|
2016-10-17 |
2024-10-15 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 바이러스 레플리콘 시스템 및 그의 용도
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
US10960070B2
(en)
*
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
CA3045650A1
(en)
|
2016-12-05 |
2018-06-14 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for enhancing gene expression
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018161092A1
(en)
|
2017-03-03 |
2018-09-07 |
New York University |
Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
|
|
EP3595676A4
(en)
*
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
ES3039647T3
(en)
|
2017-05-31 |
2025-10-23 |
Arcturus Therapeutics Inc |
Synthesis and structure of high potency rna therapeutics
|
|
SG11202005792RA
(en)
|
2017-12-20 |
2020-07-29 |
Vlp Therapeutics Llc |
Alphavirus replicon particle
|
|
JP7494117B2
(ja)
|
2018-01-19 |
2024-06-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えレプリコン系を使用する免疫応答の誘導および増強
|
|
CA3101454A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Messenger rna vaccines and uses thereof
|
|
WO2021119545A1
(en)
|
2019-12-11 |
2021-06-17 |
Gritstone Bio, Inc. |
Durable vaccination
|
|
MX2022007905A
(es)
|
2019-12-31 |
2022-08-25 |
Elixirgen Therapeutics Inc |
Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
|
|
KR20220128367A
(ko)
|
2019-12-31 |
2022-09-20 |
엘릭서젠 쎄라퓨틱스, 인크. |
Zscan4 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
|
|
EP4142786A4
(en)
|
2020-04-27 |
2024-06-19 |
Ohio State Innovation Foundation |
LIVE ATTENUATED MEASLES VIRUS VACCINE AGAINST SARS-COV-2
|
|
WO2021255270A1
(en)
|
2020-06-19 |
2021-12-23 |
Ziphius Vaccines |
Self-amplifying sars-cov-2 rna vaccine
|